Singapore – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today released the Singapore findings of its Future Health Index (FHI) 2024 report: Better care for more people, which shows that Singapore’s healthcare sector is at the forefront of generative AI investments and using technology to optimize operational efficiencies, benefiting both staff and patients.
The ninth edition of the report, which surveyed nearly 3,000 healthcare leaders in 14 countries, including Singapore, found that healthcare leaders are focusing on improving operational efficiencies through data integration and AI-enabled innovation to improve patient care amidst increasing pressures due to workforce shortages, financial challenges, and growing demand.
“While we are seeing long wait times and staff shortages making it difficult for people to get the care needed, healthcare leaders in Singapore are taking action to deliver better patient care,” said Dr Mark Burby, Vice President of Health Systems, Philips APAC. “Singapore is taking the lead in its AI investments, including in areas such as generative AI. While there is a shared understanding around the safe and responsible use of data and AI, greater cross-sector collaboration is required to drive industry standards to unlock their full potential.”
Singapore is taking the lead in its AI investments, including in areas such as generative AI. While there is a shared understanding around the safe and responsible use of data and AI, greater cross-sector collaboration is required to drive industry standards to unlock their full potential.
Dr Mark Burby
Vice President of Health Systems, Philips APAC
Urgent need to address staff shortages and financial challenges to improve patient care Amid Singapore’s healthcare talent crunch, the FHI found that half of the healthcare leaders (50%) are seeing increased burnout, stress, mental health issues, deteriorating work-life balance and low morale among existing staff. 60% of healthcare leaders are also concerned about staff shortages resulting in delays in care for patients, whether it is due to increased waiting lists for appointments (41%), longer waiting times for treatments or procedures (35%), or delayed/limited access to screening, diagnosis, and preventive care (32%). In Singapore, almost all healthcare leaders (96%) see opportunities for data-driven insights to improve care at their organization, improve healthcare access and reduce disparities in healthcare outcomes across communities. Singapore’s healthcare sector continues to have appetite for AI, with healthcare leaders already looking at the next frontier. Currently, the three biggest areas of AI implementation for clinical decision support are in in-hospital patient monitoring (67%), medication management (64%) and treatment planning (61%).
79% of healthcare leaders in Singapore also highlighted that financial challenges are impacting their organization’s ability to provide timely, high quality-care. They acknowledge that improving operational efficiencies is the best way to overcome these financial challenges, with 64% of them already implementing such solutions at their organization.
Cohesive data integration is needed to improve care and access
However, 84% also reported that they experience at least one data integration challenge which impacts care provided to patients. This leads to increased operational costs due to inefficiencies (36%), limited coordination between care providers/departments (35%), and increased risk of errors, reduced patient safety and/or quality of care (35%).
To provide better patient care to Singaporeans, healthcare leaders are thinking of ways to address challenges by first pinpointing the aspects that need improvement, which include data security/privacy (44%), the accuracy of data (42%), full patient access to their own health data (40%), and interoperability between platforms/healthcare settings (38%).
Increasing focus on AI and generative AI
Generative AI is also taking off, with Singapore being ahead of the curve. 89% of Singaporean healthcare leaders said they are currently investing or planning to invest in generative AI within the next 12 months, higher than global average of 62%. In fact, more than a third (37%) are currently investing in generative AI, highlighting their recognition of the benefits that it could bring to patient care.
While there is widespread excitement about the possibilities of AI, healthcare leaders are cognizant of the areas of concern that come with its use, including data bias. More than half of leaders find it important to ensure staff diversity in data and AI (51% vs 38% globally), to make AI transparent and interpretable for healthcare professionals (48%, same as global) and to have policies for the ethical use of data and AI (42%, on par with global at 43%). This can only be realized through cross-sector collaboration and coalition building.
“We understand that data and AI will play an even bigger role in the digital transformation of Singapore’s healthcare system. At Philips, we are committed to partnering with healthcare providers on this journey, leveraging our innovation across imaging, interventional and monitoring elevated by our AI and informatics capabilities. It is only through such partnerships within the ecosystem that patient care, workflow, and productivity can be improved,” added Dr Burby.
Philips has been working with its partners in Singapore and the APAC region on new business models and engaging in long-term strategic partnerships to innovate care delivery. Being aware that services, upgrades, sustainable innovations, and practices as well as training and education are key to the long-term success of digital transformation, Philips offers integrated and comprehensive suites of systems, smart devices, software, and services, to address the specific pain points faced by healthcare providers and ultimately help unleash the full possibilities of digital transformation.
For details on the methodology and to access this year’s report, visit Future Health Index 2024.
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.